Anticoagulation in Stent Intervention "MUSICA-2"

Active, not recruiting

Phase 4 Results N/A

Update History

25 Feb '15
A location was updated in Badalona.
New
The overall status was removed for Hospital Germans Trias i Pujol.
A location was updated in Hospitalet de Llobregat.
New
The overall status was removed for Hospital Universitari de Bellvitge.
A location was updated in Sabadell.
New
The overall status was removed for Corporación Sanitaria Parc Taulí.
A location was updated in Santander.
New
The overall status was removed for Hospital Marqués de Valdecilla.
A location was updated in Majadahonda.
New
The overall status was removed for Hospital Puerta del Hierro.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Clínic de Barcelona.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Sant Pau.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Universitario Vall d'Hebron.
A location was updated in Girona.
New
The overall status was removed for Hospital Dr.Josep Trueta.
A location was updated in Madrid.
New
The overall status was removed for Hospital San Carlos.
A location was updated in Madrid.
New
The overall status was removed for Hospital Universitario Gregorio Marañón.
6 Oct '11
The Summary of Purpose was updated.
New
Objective: The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S. Design: Randomized, parallel, with two arms, blind evaluation by third parties. Patients: 304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2), which requires prevention of thrombosis
Old
Objective: The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with atrial fibrillation, low-moderate risk of stroke (CHADS ? 2) who are undergoing PCI-S. Design: Randomized, parallel, with two arms, blind evaluation by third parties. Patients: 304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ? 2), which requires prevention of thrombosis